TL;DR: Trulieve Cannabis Corp. (NYSE: TRLV) enters the final stretch of Q2 2026 as the country’s largest cannabis retailer by dispensary count, having reduced its 2025 net loss by approximately 25% while maintaining $1.18 billion in annual revenue. Trading at a significant discount to the $19.45 average analyst price target — implying 132% upside — the Florida-headquartered MSO is positioned as one of the sector’s more compelling profitability turnaround stories heading into August earnings. Track real-time price and volume for TRLV and the broader cannabis sector via our cannabis stock tracker.
Market Analysis
Trulieve’s 2025 full-year results established a meaningful benchmark for profitability improvement in a difficult operating environment. Revenue came in at $1.18 billion, roughly flat versus 2024’s $1.19 billion — a deliberate trade-off as management focused on margin expansion and operational discipline over top-line growth. The net loss of $116.38 million represented a roughly 25% improvement over the prior year, the clearest sign yet that cost rationalization initiatives are taking hold across the retail network and processing operations.
The company’s NYSE listing has meaningfully expanded Trulieve’s institutional investor access and sell-side analyst coverage. With six analysts currently maintaining coverage and a consensus Strong Buy rating, TRLV has attracted attention from institutional funds that were previously restricted from holding OTC-listed cannabis names. The $19.45 consensus 12-month price target against the current trading price represents one of the sector’s widest implied upside spreads — a combination of deep sector-wide discount and specific optimism about Trulieve’s scale advantages.
The dispensary network remains a central investment thesis. Operating more than 130 retail locations concentrated in Florida, with additional stores in Arizona, Georgia, Ohio, Maryland, West Virginia, Connecticut, and Pennsylvania, Trulieve built its foundation on the principle that geographic density drives operating leverage. Florida remains the company’s dominant market, and with the state’s medical cannabis program consistently generating among the highest per-patient sales volumes in the country, the home market continues to function as the primary operating cash engine.
Management’s stated priorities have centered on narrowing the path to adjusted EBITDA breakeven at the operational level, with capital allocation shifting away from new-market expansion toward debt management and retail efficiency. The Q2 2026 reporting cycle, expected in August, will provide updated visibility into whether the profitability trend has continued into 2026. The company’s brand portfolio — including Modern Flower, Muse, Momenta, and Co2lors — spans price tiers from value to premium, giving Trulieve defense against consumer trade-down while preserving margin upside in the medical and premium recreational segments.
Regulatory and Market Context
The macroeconomic case for MSO profitability improvement is tied directly to the Schedule III rescheduling proceeding now in its administrative law evidence review phase. The critical financial mechanism at stake is Section 280E of the Internal Revenue Code, which currently prevents cannabis operators from deducting ordinary business expenses against federal taxable income. For Trulieve, which operates across multiple states and carries significant gross revenue, 280E represents a material cash tax burden that has suppressed reported profitability on an absolute basis.
A rescheduling outcome that reclassifies cannabis as a Schedule III controlled substance would not automatically eliminate 280E, but the prevailing legal analysis suggests Schedule III operators would no longer fall within the statute’s scope. The timing of the administrative proceeding remains uncertain, but the direction of the regulatory process has remained consistent. For investors in TRLV, the rescheduling catalyst is understood as a binary event that would fundamentally reset the profitability calculus without requiring any operational change at the company level.
In the broader MSO landscape, the sector has navigated a prolonged period of multiple compression and capital scarcity. The MSOS ETF’s 50% year-over-year recovery reflects improving institutional sentiment, but the path from recovery to sustained re-rating will require operators to demonstrate consistent earnings growth over multiple quarters. Trulieve’s scale — $1.18 billion in annual revenue and more than 130 retail touchpoints — positions it among the few US cannabis companies capable of generating meaningful operating leverage once the tax environment normalizes.
Conclusion
Trulieve’s August 2026 earnings report will serve as a real-time test of whether the profitability improvement trajectory established in 2025 has continued into the current year. Management’s focus on operational discipline, retail network efficiency, and the Florida core market creates a clear analytical framework for evaluating Q2 results against both internal targets and sector benchmarks. Against a consensus price target that implies more than 130% upside from current levels, TRLV sits in a category of deep-value MSO names that the sector’s most constructive analysts have consistently identified as misvalued relative to fundamental earnings power. The rescheduling process remains the sector-level catalyst; Trulieve’s execution narrative will determine whether it emerges as one of the primary beneficiaries. Investors following TRLV and the full cannabis market intelligence universe can monitor real-time data through our cannabis stock tracker.